Company
Abingdon Health plc
Headquarters: York, United Kingdom
Employees: 164
CEO: Mr. Chris Henry Francis Yates
Market Cap
£13.3 Million
GBP as of July 1, 2025
US$18.2 Million
Abingdon Health plc Categories
United Kingdom Healthcare Diagnostics & ResearchUnited Kingdom Healthcare United Kingdom Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $162.07 B |
| Danaher | $144.92 B |
| Siemens Healthineers AG | $64.17 B |
| Lonza Group Ltd | $49.67 B |
| IDEXX Laboratories, Inc. | $43.99 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.
Financials
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £5.3 M |
| EBITDA | £-1,943,000 |
| Gross Profit TTM | £2.1 M |
| Profit Margin | -41.82% |
| Operating Margin | -60.75% |
| Quarterly Revenue Growth | 116.90% |
Stocks & Indices
Abingdon Health plc has the following listings and related stock indices.
Stock: LSE: ABDX wb_incandescent